🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us at the RENALC-BLADDR-PROSCA 2025 hybrid global forum on GU Oncology this December in Lisbon! Dive into the latest evidence with top experts using the Mirrors of Medicine™ case-based approach. 🐦Early bird registration is now open!➡️ Register now: gu-global-forum.org/registration-2…

📢 Big news! Prostate Cancer and Prostatic Diseases has reached a new Impact Factor of 5.8! A strong recognition of the quality and relevance of our research in the field of urology. Thank you to our authors, reviewers, and readers! #Urology #ProstateCancer #ImpactFactor

Fully agree. Don’t render patients incurable based on PSMA alone! Karim Touijer Alberto Briganti Thomas Zilli Giorgio Gandaglia CFSpic Juan Gómez Rivas

#ESTRO25 insights from the #SystemicTherapy Focus Group — from novel treatment combinations that include #radiotherapy to cutting-edge trials such as STORM/PEACE-V & PORTEC-4a. 👉 bit.ly/4n1fdzw

Fantastic experience #UROonco25 in🔥Sevilla! Fantastic organization by Alessandro Volpe & #ESOU Board Thank you for the opportunity to speak, moderate, share knowledge & experiences, and learn from experts You work hard, but you always come back home #enriched from professional and

#AxelBex #JensBedke nirm Selcuk Erdem Grant Stewart Alessandro Volpe Antonio Alcaraz #JeanChristopheBernhard Roberto Iacovelli Morgan Roupret European Urology Oncology Bernadett Szabados Thomas Zilli EAU YAU Prostate Cancer Working Group EAU YAU Urothelial Carcinoma EAU-YAU Renal Cancer Working Group EAU Young Academics European School of Urology (EAU ESU) Daniele Amparore

🎯 Off to 🇮🇹 #SummerSchoolNegrar next week! Excited to learn, connect & share with great colleagues 🌍 🙏 Thanks to the team , esp. Filippo Alongi & @LucaNicosia — for making it happen! 📚 Let’s talk #RadiationOncology 🔗 summerschoolnegrar.com #Oncology #MedEd

Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from Vérane Achard in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍

First day at the III Summer School of Clinical Adaptive Radiotherapy in Negrar. 3 days of lessons and hands-on sessions on #adaptiveradiotherapy Happy to learn from our incredible Faculty. #radonc #radiotherapy #mrlinac #prostatecancer Elekta

International experts/panelist of this morning at 3d summer school of adaptive radiotherapy in Negrar!! summerschoolnegrar.com #radoncs

✅ First day at the Summer School! 🌍 25 students from all continents 👨‍🏫 Honored to be part of a top-level faculty 🔝 🎯 Spoke about adaptive radiotherapy in bladder cancer 🚀 Great energy and interaction! #RadOnc #AdaptiveRT #BladderCancer #OncologyEducation #GlobalOncology

💥 PEACE-V STORM final results at #ESTRO25: ENRT beats MDT for oligorecurrent nodal prostate cancer. ✔️ Better MFS (76% vs. 63%) ✔️ Improved control ✔️ Similar toxicity, fewer treatments 👉 bit.ly/46bHU6N Piet Ost Thomas Zilli

'Better technology cures more patients with less side effects' quoting Alison Tree 💙 at the MR and RT symposium in Zurich today! #radiotherapy #ProstateCancer #RadoncGU

Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration

Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial sciencedirect.com/science/articl… This long-term follow-up study from the GÖTEBORG-1 screening trial evaluated outcomes in 488 men with

(43) Due tecnici di radiologia medica | Ente Ospedaliero Cantonale (EOC) | LinkedIn linkedin.com/jobs/view/4259…

Can clinical complete response replace cystectomy in MIBC? The EORTC STARBURST project aims to validate MRI + biomarkers to predict response to neoadjuvant therapy—opening the door to personalized, bladder-sparing strategies. 🔗 euoncology.europeanurology.com/article/S2588-… #BladderCancer #MIBC

👀Not cancer but promising concept/result. As we expand the indication of #radiotherapy this could be an area of active interest. Sameer Keole ASTRO thelancet.com/journals/lance…

youtu.be/Ylxi-YhR3ZQ

Adjuvant Chemoradiation & Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer JAMA Oncology doi.org/10.1001/jamaon… 🔎🇨🇳phs-2 trial 👉Camrelizumab > cape + RT vs obs. 👉3-year OS rate: 58.2 vs 30.5% 🧐Supports adj. Tx, ARTEMIDE-Biliary01 awaited ESMO - Eur. Oncology EASL Education